August 14, 2025

Thai Trial Tests Turmeric Emulgel Skin Safety

Thai investigators test a botanical emulgel formulation to identify early safety signals related to skin irritation and allergenicity before advancing to patient trials.

Conexiant

August 04, 2025

Beta-HPV–Driven SCC Resolved After TCR Signaling Correction

Case study shows cutaneous squamous cell carcinoma linked to beta-human papillomavirus cleared following T-cell immune restoration.

Conexiant

July 29, 2025

Nonblistering Papules: Genetic Mystery Cracked

A woman with a decades-long history of intensely pruritic, nonblistering papules on her extremities was diagnosed with dystrophic epidermolysis bullosa pruriginosa, confirmed by COL7A1 gene sequencing, after a comprehensive clinicopathologic evaluation.

Conexiant

July 25, 2025

Spontaneous Urticaria Carries Greater Burden, Costs

Researchers assess how disease type, comorbidities, and treatment knowledge shape clinical outcomes and healthcare use in patients with chronic urticaria.

Conexiant

July 22, 2025

Might That Lip Lesion Be BCC?

New research has documented 4 cases of lip basal cell carcinoma presenting as smooth yellow nodules—a rare clinical presentation that may be mistaken for benign mesenchymal tumors, potentially resulting in diagnostic delays and postponed treatment.

Conexiant

July 14, 2025

Self-Injection Device Effective for Acne Lesions

A new multicenter trial found that self-injected low-dose triamcinolone using an assistance device was as effective and safe as physician-administered injections for inflammatory acne, with improved outcomes at higher doses for severe lesions.

Conexiant

April 19, 2024

Dosing Proceeds in GA Study

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

New Retinal Physician

April 17, 2023

Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma

Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by...

The ASCO Post

April 29, 2024

First Death From Alaskapox Reported

Alaska health officials warned of the risk of Alaskapox in the wake of the first death from the disease in January 2024.

Conexiant